Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free
Technology for LAMP-vax Vaccines
TIGARD, Oregon and Hershey, Pennsylvania December 15, 2014
TIGARD, Ore., December 15, 2014 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC
Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today
announced that it has entered into an agreement with Immunomic Therapeutics, Inc. (“ITI”) for
the use of Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ vaccine
platform. In the agreement, ITI receives an option for an exclusive Worldwide license to the
Biojector®-2000 that triggers based on the achievement of certain clinical milestones. In
addition, the agreement contains provisions for development rights and exclusive license of
Bioject’s ID Pen intradermal injection system for various fields of use.
"Bioject’s needle-free intradermal injection devices have a strong track record of clinical benefit
with DNA vaccines” said Mark Logomasini, President and CEO of Bioject.” These benefits have
been demonstrated in several programs at ITI. This agreement establishes a framework for
bringing these programs and their associated products to market. We are very much looking
forward to continued work with the team at ITI.”
Bioject's advanced needle-free technology works by forcing liquid medication at high speed
through a tiny orifice held against the skin. The diameter of the orifice is smaller than the
diameter of a human hair. This creates an ultra-fine stream of medicine able to penetrate skin
without use of a needle. Bioject's technology is available for use with a wide range of injectable
drugs and has the ability to deliver medicine at a range of depths and injection volumes.
Immunomic Therapeutics (ITI) is a rapidly growing biotechnology company pioneering
breakthrough vaccines. ITI’s LAMP-vax has been described as the missing link in enhancing the
effectiveness of DNA vaccines. LAMP immunotherapy formulations have been safely applied
and immunogenic for patients with prostate cancer, acute myeloid leukemia and melanoma.
ITI has made great progress over the past few years and has emerged with a new class of DNAbased
allergy immunotherapeutic vaccines poised to potentially transform the worldwide allergy
market. The company believes that Bioject’s novel delivery technologies hold promise to deliver
LAMP-vax vaccines to the right populations of cells in the right part of the body and further
strengthen the application of ITI core technology, first in allergies and in other
immunotherapeutic areas.
“The right delivery is key to a well-designed vaccine approach. In our hands, we have shown that
LAMP-vax delivered with Bioject has the potential to enhance the right kind of immune
response to our vaccines while providing a safe delivery method. I am excited about the potential
of this collaboration to further support acceleration of our product development,” said Teri
Heiland, ITI VP of R&D.
